Wilson Sonsini advised NAPIGEN on the deal. NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, announced the completion of $7.85 million seed...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here